Progentos discovers and develops first-in-class small‑molecule drugs that induce endogenous oligodendrocyte progenitor cells to remyelinate axons damaged by demyelinating diseases such as multiple sclerosis. Its proprietary molecules reportedly outperform previous approaches at differentiating OPCs into new oligodendrocytes and regenerate myelin in in vivo models. The company announced its launch concurrent with this financing and plans to advance its MS program into human proof-of-concept studies. Progentos also intends to expand its pipeline into additional degenerative diseases. The company will operate from Watertown, Massachusetts and Naarden, The Netherlands. Management emphasizes the unmet need for therapies that restore function by regenerating myelin.

Total raised

$65M

Funding rounds

1

Latest round

Series A

Latest activity

May 2024